Primary-Prevention Data Should Boost Uptake Of Amgen’s Repatha

Tough Competition Looms

 
• By Alaric DeArment
  
Close up of Amgen sign at its headquarters in Thousand Oaks, California, USA
Amgen announced results from the Phase III VESALIUS-CV trial of Repatha. • Source: Shutterstock

More from Clinical Trials

More from R&D